# hotspotthera.com

> AI-optimized mirror of hotspotthera.com containing 181 pages totalling 85,670 words of clean markdown content, structured data, and semantic HTML. Original source: https://hotspotthera.com. Last updated: 2026-07-26T03:58:03.879Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [Home - HotSpot Therapeutics](/content/site-root.html) (189 words)

## Articles & Blog Posts

- [Loretta Tse, PhD - HotSpot Therapeutics](/content/person/loretta-tse-ph-d/index.html) (17 words)
- [Niti Goel, MD - HotSpot Therapeutics](/content/person/niti-goel-md/index.html) (13 words)
- [Eva Jack - HotSpot Therapeutics](/content/person/eva-jack/index.html) (19 words)
- [Andrew Morton - HotSpot Therapeutics](/content/person/andrew-morton/index.html): , Andrew Morton brings nearly 15 years of finance and accounting experience in the life sciences/healthcare/biotechnology sector. He joins the HotSpot from Gemini Therapeutics where he served as Vice President of Finance. Prior to joining Gemini, Andrew held leadership roles in the finance function at Ra Pharmaceuticals, pre-IPO through the Company’s acquisition by UCB, Inc in 2020. Prior to joining Ra Pharma, Andrew held positions of increasing responsibility at Tetraphase Pharmaceuticals. Andrew obtained his B.S. in Business Administration from Northeastern University in Boston, Massachusetts. (19 words)
- [Joe Wahle, PhD - HotSpot Therapeutics](/content/person/joe-wahle/index.html) (16 words)
- [Alison O'Neill, M.D. - HotSpot Therapeutics](/content/person/alison-oneill-m-d/index.html) (13 words)
- [Tim Reilly, PhD - HotSpot Therapeutics](/content/person/tim-reilly/index.html) (16 words)
- [Fang Wang, PhD - HotSpot Therapeutics](/content/person/fang-wang/index.html) (20 words)
- [Tony Ho, MD - HotSpot Therapeutics](/content/person/ash-khanna/index.html) (19 words)
- [Bruce Booth, PhD - HotSpot Therapeutics](/content/person/bruce-booth/index.html) (17 words)
- [Daniel Omstead, PhD - HotSpot Therapeutics](/content/person/daniel-omstead/index.html) (13 words)
- [Jill Carroll - HotSpot Therapeutics](/content/person/jill-carroll/index.html) (16 words)
- [Victoria Richon, PhD - HotSpot Therapeutics](/content/person/victoria-richon/index.html) (16 words)
- [wp-content/uploads/2023/01/poster-hotspot-therapeutics-sitc-october_2022_mlr-pdf.html](/content/wp-content/uploads/2023/01/poster-hotspot-therapeutics-sitc-october_2022_mlr-pdf.html) (969 words)
- [press_release/abbvie-launches-strategic-collaboration-with-hotspot-therapeutics-to-further-expand-immunology-pipeline.html](/content/press_release/abbvie-launches-strategic-collaboration-with-hotspot-therapeutics-to-further-expand-immunology-pipeline.html) (856 words)
- [wp-content/uploads/2024/09/presentation-hotspot-esmo-2024-first-in-human-fih-phase-1-data-of-hst-1011-an-oral-cbl-b-inhibitor-in-patients-with-advanced-solid-tumors-pdf.html](/content/wp-content/uploads/2024/09/presentation-hotspot-esmo-2024-first-in-human-fih-phase-1-data-of-hst-1011-an-oral-cbl-b-inhibitor-in-patients-with-advanced-solid-tumors-pdf.html) (1,346 words)
- [wp-content/uploads/2023/05/phase-1-2-study-of-hst-1011-an-oral-cbl-b-inhibitor-alone-and-in-combination-with-anti-pd-1-in-patients-with-advanced-solid-tumors-pdf.html](/content/wp-content/uploads/2023/05/phase-1-2-study-of-hst-1011-an-oral-cbl-b-inhibitor-alone-and-in-combination-with-anti-pd-1-in-patients-with-advanced-solid-tumors-pdf.html) (922 words)
- [wp-content/uploads/2023/01/poster-hotspot-therapeutics_sitc_2021-pdf.html](/content/wp-content/uploads/2023/01/poster-hotspot-therapeutics_sitc_2021-pdf.html) (936 words)
- [wp-content/uploads/2023/01/poster-hotspot-therapeutics-sitc-october_2022_in_vivo-pdf.html](/content/wp-content/uploads/2023/01/poster-hotspot-therapeutics-sitc-october_2022_in_vivo-pdf.html) (948 words)
- [wp-content/uploads/2023/01/poster-hotspot-therapeutics_aacr_2022-pdf.html](/content/wp-content/uploads/2023/01/poster-hotspot-therapeutics_aacr_2022-pdf.html) (833 words)
- [wp-content/uploads/2023/05/inhibition-of-the-e3-ligase-cbl-b-enhances-the-effector-function-and-proliferation-of-natural-killer-nk-cells-pdf.html](/content/wp-content/uploads/2023/05/inhibition-of-the-e3-ligase-cbl-b-enhances-the-effector-function-and-proliferation-of-natural-killer-nk-cells-pdf.html) (971 words)
- [wp-content/uploads/2024/11/poster-hotspot_sitc_october_2024-final-pdf.html](/content/wp-content/uploads/2024/11/poster-hotspot_sitc_october_2024-final-pdf.html) (739 words)
- [16:9 Poster Template](/content/wp-content/uploads/2023/11/exploring-proximal-biomarkers-of-cbl-b-inhibition-in-human-peripheral-blood-mononuclear-cells-sitc-2023-pdf.html) (811 words)
- [wp-content/uploads/2024/10/poster-hotspot_poster_aacr_triple_october_2024-final-pdf.html](/content/wp-content/uploads/2024/10/poster-hotspot_poster_aacr_triple_october_2024-final-pdf.html) (775 words)
- [wp-content/uploads/2025/07/poster-esmo-gi_2025_125p_final-pdf.html](/content/wp-content/uploads/2025/07/poster-esmo-gi_2025_125p_final-pdf.html) (586 words)
- [wp-content/uploads/2024/08/malt1-poster-aacr-lymphoma-conference-2024-pdf-pdf.html](/content/wp-content/uploads/2024/08/malt1-poster-aacr-lymphoma-conference-2024-pdf-pdf.html) (646 words)
- [wp-content/uploads/2026/06/20260512_eular-poster-final-pdf.html](/content/wp-content/uploads/2026/06/20260512_eular-poster-final-pdf.html) (518 words)
- [wp-content/uploads/2025/07/poster-esmo-gi_2025_-124p_final-pdf.html](/content/wp-content/uploads/2025/07/poster-esmo-gi_2025_-124p_final-pdf.html) (547 words)
- [wp-content/uploads/2026/03/preclinical-evaluation-of-irf5-small-molecule-inhibitors-with-potent-activity-in-lupus-relevant-systems-final-poster-march-2026-pdf.html](/content/wp-content/uploads/2026/03/preclinical-evaluation-of-irf5-small-molecule-inhibitors-with-potent-activity-in-lupus-relevant-systems-final-poster-march-2026-pdf.html) (429 words)
- [16:9 Poster Template](/content/wp-content/uploads/2025/06/poster-hotspot-therapeutics-focis-june-2025-1-pdf.html) (468 words)
- [News - HotSpot Therapeutics](/content/news/index.html) (2,340 words)
- [Page not found - HotSpot Therapeutics](/content/press_releases/hotspot-therapeutics-closes-100m-series-c-t-5b-e2-80-a6-5d-in-class-allosteric-drug-discovery-platform-to-the-clinic.html) (28 words)
- [Allokraft - HotSpot Therapeutics](/content/allokraft/index.html) (1,236 words)
- [Terms and conditions - HotSpot Therapeutics](/content/terms-and-conditions/index.html): Terms and conditions 1. Acceptance of the Terms and Conditions. 1.1 HotSpot Therapeutics, Inc. (herein referred to as “HotSpot,”, “HotSpot... (2,687 words)
- [wp-content/uploads/2023/12/2023_ash_discovery-of-the-first-malt1-allosteric-scaffolding-inhibitor-pdf.html](/content/wp-content/uploads/2023/12/2023_ash_discovery-of-the-first-malt1-allosteric-scaffolding-inhibitor-pdf.html) (310 words)
- [HotSpot Therapeutics Presents Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-preclinical-data-from-small-molecule-cbm-signalosome-inhibitor-program-at-esmo-gastrointestinal-cancers-congress-2025.html): BOSTON, Mass., July 4, 2025 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (515 words)
- [HotSpot Therapeutics Completes $45 Million Series A Financing to Advance New Approach to Allosteric Drug Discovery - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-completes-45-million-series-a-financing-to-advance-new-approach-to-allosteric-drug-discovery.html): “HotSpot is targeting natural regulatory sites on proteins that evolution has perfected over many millions of years. This allows us... (1,089 words)
- [Evan Friedman - HotSpot Therapeutics](/content/person/evan-friedman/index.html) (13 words)
- [Kenneth Carson - HotSpot Therapeutics](/content/person/kenneth-carson/index.html) (16 words)
- [Paul Thibodeau, PhD - HotSpot Therapeutics](/content/person/paul-thibodeau/index.html) (17 words)
- [Graziano Seghezzi - HotSpot Therapeutics](/content/person/graziano-seghezzi/index.html) (20 words)
- [Geraldine Harriman, PhD - HotSpot Therapeutics](/content/person/geraldine-harriman/index.html) (14 words)
- [Fouad Azzam, PhD - HotSpot Therapeutics](/content/person/fouad-azzam/index.html) (21 words)
- [Jonathan Montagu - HotSpot Therapeutics](/content/person/jonathan-montagu/index.html) (19 words)
- [Jose “Pepe” Carmona - HotSpot Therapeutics](/content/person/jose-pepe-carmona/index.html) (21 words)
- [Stephanie Krebs - HotSpot Therapeutics](/content/person/stephanie-krebs/index.html): , Vice President Business Development Partnering Licensing (18 words)
- [W. Adam Hill - HotSpot Therapeutics](/content/person/w-adam-hill/index.html) (22 words)
- [Michael Tota - HotSpot Therapeutics](/content/person/michael-tota/index.html) (19 words)
- [Peter Fekkes - HotSpot Therapeutics](/content/person/peter-fekkes/index.html) (19 words)
- [Henry Skinner - HotSpot Therapeutics](/content/person/henry-skinner/index.html) (32 words)
- [John Doe - HotSpot Therapeutics](/content/person/john-doe/index.html) (17 words)
- [Samantha Truex - HotSpot Therapeutics](/content/person/samantha-truex/index.html) (13 words)
- [HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-preclinical-data-from-small-molecule-irf5-inhibitor-program-at-eular-2026.html): BOSTON, Mass., June 4, 2026 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric... (569 words)
- [AbbVie Launches Strategic Collaboration with HotSpot Therapeutics to Further Expand Immunology Pipeline - HotSpot Therapeutics](/content/press_release/abbvie-launches-strategic-collaboration-with-hotspot-therapeutics-to-further-expand-immunology-pipeline-2.html): NORTH CHICAGO, Ill. and BOSTON, Mass., December 06, 2022 – AbbVie (NYSE: ABBV) and HotSpot Therapeutics, Inc., a biotechnology company... (851 words)
- [HotSpot Therapeutics Presents Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-pre-clinical-data-on-cbl-b-program-at-american-association-for-cancer-research-annual-meeting-2022.html): BOSTON, Mass., Apr. 8, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and... (658 words)
- [Science - HotSpot Therapeutics](/content/science/index.html) (298 words)
- [Pipeline - HotSpot Therapeutics](/content/pipeline/index.html) (838 words)
- [HotSpot Therapeutics Presents First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-first-in-human-phase-1-clinical-data-on-its-novel-cbl-b-inhibitor-hst-1011-at-esmo-congress-2024.html): BOSTON, Mass., September 12, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (681 words)
- [HotSpot Therapeutics and Caris Life Sciences Announce Collaboration to Advance Precision Medicine Development for Difficult-to-Drug Therapeutic Targets - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-and-caris-life-sciences-announce-collaboration-to-advance-precision-medicine-development-for-difficult-to-drug-therapeutic-targets.html): , Preferred portfolio partnership with Caris will streamline development of Hotspot’s portfolio by integrating broad tissue and liquid molecular profiling, artificial intelligence driven mining of large datasets, and clinical-translational innovations to deliver novel allosteric medicines to patients (931 words)
- [HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-preclinical-data-from-small-molecule-irf5-inhibitor-program-at-15th-european-lupus-meeting.html): BOSTON, Mass., March 4, 2026 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric... (491 words)
- [HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-preclinical-data-from-small-molecule-irf5-program-at-focis-2025.html): BOSTON, Mass., June 25, 2025 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (479 words)
- [HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-preclinical-data-for-potential-first-in-class-malt1-scaffolding-inhibitor-at-the-4th-aacr-international-meeting-advances-in-malignant-lymphoma.html): BOSTON, Mass., Jun. 20, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (506 words)
- [HotSpot Therapeutics secures $100M to advance allosteric platform - HotSpot Therapeutics](/content/news_reference/hotspot-therapeutics-secures-100m-to-advance-allosteric-platform.html) (17 words)
- [HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-preclinical-data-from-small-molecule-irf5-inhibitor-program-at-eular-2026.html): BOSTON, Mass., May 20, 2026 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric... (270 words)
- [HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at AACR Annual Meeting 2023 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-preclinical-data-from-cbl-b-program-at-aacr-annual-meeting-2023.html): Preclinical data highlighted ability of HotSpot’s CBL-B inhibitors to enhance the effector function and proliferation of natural killer cells, which... (577 words)
- [Cancer-Targeting Biotech Startup HotSpot Therapeutics Raises $100M - HotSpot Therapeutics](/content/news_reference/cancer-targeting-biotech-startup-hotspot-therapeutics-raises-100m.html) (16 words)
- [HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Inhibitor Program at 15th European Lupus Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-preclinical-data-from-small-molecule-irf5-inhibitor-program-at-15th-european-lupus-meeting.html): BOSTON, Mass., February 26, 2026 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric... (272 words)
- [AbbVie offers up to $335M for connection with HotSpot’s preclinical small-molecule program - HotSpot Therapeutics](/content/news_reference/abbvie-offers-up-to-335m-for-connection-with-hotspots-preclinical-small-molecule-program.html): AbbVie has formed a connection with HotSpot Therapeutics, inking a global licensing option deal for the biotech’s preclinical small-molecule allosteric therapy and extending the opportunity for up to $295 million in biobucks. (13 words)
- [SR One fuels HotSpot's $65M B round to fund allosteric R&D - HotSpot Therapeutics](/content/news_reference/sr-one-fuels-hotspots-65m-b-round-to-fund-allosteric-rd.html) (16 words)
- [HotSpot Therapeutics Presents Preclinical Data for Potential First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-preclinical-data-for-potential-first-in-class-malt1-scaffolding-inhibitor-at-65th-ash-annual-meeting.html): BOSTON, Mass., Dec. 11, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (556 words)
- [HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic - HotSpot Therapeutics](/content/news_reference/hotspot-therapeutics-adds-65m-to-steer-allosteric-medicines-to-the-clinic.html) (13 words)
- [HotSpot Therapeutics Presents Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-additional-phase-1-biomarker-data-on-novel-cbl-b-inhibitor-hst-1011-at-2024-society-for-immunotherapy-of-cancer-annual-meeting.html): BOSTON, Mass., November 7, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (439 words)
- [Boston's HotSpot Therapeutics Eyes The Clinic Following $65 Million Series B - HotSpot Therapeutics](/content/news_reference/bostons-hotspot-therapeutics-eyes-the-clinic-following-65-million-series-b.html) (13 words)
- [HotSpot Therapeutics Achieves First-In-Human Dosing with HST-1011, An Investigational Oral Small Molecule Allosteric Inhibitor of CBL-B - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-achieves-first-in-human-dosing-with-hst-1011-an-investigational-oral-small-molecule-allosteric-inhibitor-of-cbl-b.html):   Phase 1/2 study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary clinical activity of HST-1011 dosed as... (730 words)
- [Atlas-backed startup raises $100M for protein 'hotspots' - HotSpot Therapeutics](/content/news_reference/atlas-backed-startup-raises-100m-for-protein-hotspots.html) (16 words)
- [HotSpot Therapeutics to Present Additional Preclinical Data on Potential First-in-Class MALT1 Scaffolding Inhibitor at the 4th AACR International Meeting: Advances in Malignant Lymphoma - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-additional-preclinical-data-on-potential-first-in-class-malt1-scaffolding-inhibitor-at-the-4th-aacr-international-meeting-advances-in-malignant-lymphoma.html): BOSTON, Mass., May 20, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (293 words)
- [HotSpot Therapeutics to Present Preclinical Data from Small Molecule IRF5 Program at FOCIS 2025 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-preclinical-data-from-small-molecule-irf5-program-at-focis-2025.html): BOSTON, Mass., June 18, 2025 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (283 words)
- [HotSpot heads for clinic with $65M series B round to develop allosteric modulators - HotSpot Therapeutics](/content/news_reference/hotspot-heads-for-clinic-with-65m-series-b-round-to-develop-allosteric-modulators.html) (13 words)
- [AbbVie puts up $40M to license a treatment from HotSpot Therapeutics - HotSpot Therapeutics](/content/news_reference/abbvie-puts-up-40m-to-license-a-treatment-from-hotspot-therapeutics.html): HotSpot Therapeutics has managed to gain some steam financially in the past few years, as the company wrangled several multi-million dollar raises. But its latest deal not only puts more cash into its pockets, it also connects with a major name in pharma. (14 words)
- [Careers - HotSpot Therapeutics](/content/careers/index.html) (455 words)
- [HotSpot Therapeutics to Present Preclinical Data from Small Molecule CBM Signalosome Inhibitor Program at ESMO Gastrointestinal Cancers Congress 2025 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-preclinical-data-from-small-molecule-cbm-signalosome-inhibitor-program-at-esmo-gastrointestinal-cancers-congress-2025.html): BOSTON, Mass., June 26, 2025 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (315 words)
- [Boston Neighbors Net $256 Million for Treg and Allosteric Therapies - HotSpot Therapeutics](/content/news_reference/boston-neighbors-net-256-million-for-treg-and-allosteric-therapies.html) (21 words)
- [HotSpot announces $65M Series B, as Nimbus pioneers look to keep up in a crowding field - HotSpot Therapeutics](/content/news_reference/hotspot-announces-65m-series-b-as-nimbus-pioneers-look-to-keep-up-in-a-crowding-field.html): In the decade since Nimbus Therapeutics built a company around computation and little-known phenomena allosteric regulation, the industry has brimmed with algorithm companies and even a few chasing those same targets. Still, a couple of the old leaders think they can keep an edge. (17 words)
- [HotSpot Therapeutics snags $100M series C to bring allosteric meds into the clinic - HotSpot Therapeutics](/content/news_reference/hotspot-therapeutics-snags-100m-series-c-to-bring-allosteric-meds-into-the-clinic.html) (19 words)
- [HotSpot gets hotter with $100M raise to push toward clinic - HotSpot Therapeutics](/content/news_reference/hotspot-gets-hotter-with-100m-raise-to-push-toward-clinic.html) (13 words)
- [HotSpot Therapeutics Appoints Alison O’Neill, M.D., as Chief Medical Officer - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-appoints-alison-oneill-m-d-as-chief-medical-officer.html): BOSTON, Mass., September 19, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (488 words)
- [Scientist, Biochemistry - HotSpot Therapeutics](/content/job/scientist-biochemistry/index.html): At HotSpot, we’re not just looking for the brightest minds or for the most brilliant individual contributors. We want passionate... (757 words)
- [HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-appoints-paul-thibodeau-ph-d-as-chief-business-officer.html): BOSTON, Mass., July 25, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule... (456 words)
- [Hotspot’s $65M series B to propel it into the clinic - HotSpot Therapeutics](/content/news_reference/hotspots-65m-series-b-to-propel-it-into-the-clinic/index.html) (15 words)
- [HotSpot Therapeutics to Present Additional Phase 1 Biomarker Data on Novel CBL-B Inhibitor HST-1011 at 2024 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-additional-phase-1-biomarker-data-on-novel-cbl-b-inhibitor-hst-1011-at-2024-society-for-immunotherapy-of-cancer-annual-meeting.html): BOSTON, Mass., October 4, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (326 words)
- [HotSpot Therapeutics Presents Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-preclinical-data-from-malt1-cbm-signalosome-glue-program-at-36th-eortc-nci-aacr-symposium.html): BOSTON, Mass., October 23, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (438 words)
- [HotSpot acquires DNA-encoded library firm Macroceutics - HotSpot Therapeutics](/content/news_reference/hotspot-acquires-dna-encoded-library-firm-macroceutics.html): HotSpot Therapeutics, a biotech firm that launched last year to develop allosteric inhibitors for autoimmune and metabolic diseases, has acquired Macroceutics, a 5-year-old provider of DNA-encoded library screening technologies. (20 words)
- [Getting higher-quality hits out of DNA-encoded libraries - HotSpot Therapeutics](/content/news_reference/getting-higher-quality-hits-out-of-dna-encoded-libraries.html): DNA-encoded libraries are quickly surpassing traditional high throughput screens as industry’s first stop for hit generation. Now, developers are taking the technology up a notch to get more tractable hits in the output. (13 words)
- [HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-preclinical-data-from-cbl-b-program-at-2022-society-for-immunotherapy-of-cancer-annual-meeting.html): BOSTON, Mass., November 10, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of orally delivered,... (539 words)
- [HotSpot Therapeutics Appoints Jose Carmona to Board of Directors - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-appoints-jose-carmona-to-board-of-directors.html): BOSTON, Mass., July 19, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule... (521 words)
- [HotSpot Therapeutics to Present Preclinical Data from MALT1 CBM Signalosome Glue Program at 36th EORTC-NCI-AACR Symposium - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-preclinical-data-from-malt1-cbm-signalosome-glue-program-at-36th-eortc-nci-aacr-symposium.html): BOSTON, Mass., October 9, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (281 words)
- [HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-preclinical-data-from-cbl-b-program-at-2023-society-for-immunotherapy-of-cancer-annual-meeting.html): BOSTON, Mass., Sep. 27, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (378 words)
- [HotSpot Therapeutics to Present New Data Indicating Successful Targeting of CBL-B at 2021 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-new-data-indicating-successful-targeting-of-cbl-b-at-2021-society-for-immunotherapy-of-cancer-annual-meeting.html): Boston, Mass., Nov. 9, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first-in-class allosteric... (670 words)
- [Smart Allostery™ - HotSpot Therapeutics](/content/smart-allostery/index.html) (303 words)
- [HotSpot Therapeutics Closes $100M Series C to Advance First-in-Class Allosteric Drug Discovery Platform to the Clinic - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-closes-100m-series-c-to-advance-first-in-class-allosteric-drug-discovery-platform-to-the-clinic.html): , Series C financing to fuel HotSpot’s transition into a clinical development company while enabling expansion of its product pipeline (671 words)
- [HotSpot Acquires Macroceutics for focused allosteric library - HotSpot Therapeutics](/content/news_reference/hotspot-acquires-macroceutics-for-focused-allosteric-library.html): HotSpot is adding a key piece to its allosteric inhibitor platform through the acquisition of DNA-encoded library company Macroceutics: the technology to make chemical libraries tailored to allosteric, rather than active, sites. (13 words)
- [HotSpot Therapeutics to Present Initial First-in-Human Phase 1 Clinical Data on its Novel CBL-B Inhibitor, HST-1011, at ESMO Congress 2024 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-initial-first-in-human-phase-1-clinical-data-on-its-novel-cbl-b-inhibitor-hst-1011-at-esmo-congress-2024.html): BOSTON, Mass., July 17, 2024 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (328 words)
- [HotSpot Therapeutics Expands Board of Directors and Management Team - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-expands-board-of-directors-and-management-team.html): CAMBRIDGE, Mass. (October 30th, 2018) – HotSpot Therapeutics, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance... (711 words)
- [HotSpot Therapeutics Presents Preclinical Data from CBL-B Program at 2023 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-presents-preclinical-data-from-cbl-b-program-at-2023-society-for-immunotherapy-of-cancer-annual-meeting.html): BOSTON, Mass., Nov. 3, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (540 words)
- [HotSpot Therapeutics to Introduce First-in-Class MALT1 Scaffolding Inhibitor at 65th ASH Annual Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-introduce-first-in-class-malt1-scaffolding-inhibitor-at-65th-ash-annual-meeting.html): BOSTON, Mass., Nov. 2, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (428 words)
- [Allostery: Realizing The Promise - HotSpot Therapeutics](/content/news_reference/allostery-realizing-the-promise/index.html): With the discovery of the first allosteric inhibitors for bcr-abl that could offer the first clinical cures for CML, allosteric drug discovery is undergoing a resurgence. (19 words)
- [HotSpot Therapeutics to Present Pre-Clinical Data on CBL-B Program at American Association for Cancer Research Annual Meeting 2022 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-pre-clinical-data-on-cbl-b-program-at-american-association-for-cancer-research-annual-meeting-2022.html): BOSTON, Mass.,  Mar. 8, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and... (295 words)
- [HotSpot Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-at-the-piper-sandler-33rd-annual-healthcare-conference.html): Boston, Mass., Nov. 16, 2021 — HotSpot Therapeutics, Inc., a biotechnology company pioneering thediscovery and development of first-in-class allosteric therapies... (239 words)
- [Senior Research Data Engineer - HotSpot Therapeutics](/content/job/senior-research-data-engineer/index.html): About HotSpot Therapeutics, Inc. At HotSpot Therapeutics, nature is inspiring us to create a wave of new medicines. Through a... (748 words)
- [HotSpot Therapeutics Completes $65 Million Series B Financing to Advance Pipeline of Novel Allosteric Medicines - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-completes-65-million-series-b-financing-to-advance-pipeline-of-novel-allosteric-medicines.html): BOSTON, Mass. (May 21, 2020) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric... (672 words)
- [HotSpot Therapeutics Announces FDA Clearance of IND Application for HST-1011, An Investigational Small Molecule Allosteric Inhibitor of CBL-B - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-announces-fda-clearance-of-ind-application-for-hst-1011-an-investigational-small-molecule-allosteric-inhibitor-of-cbl-b.html): BOSTON, Mass., January 03, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (531 words)
- [HotSpot Therapeutics debuts with $45 million to pursue allosteric inhibitors - HotSpot Therapeutics](/content/news_reference/hotspot-therapeutics-debuts-with-45-million-to-pursue-allosteric-inhibitors.html): HotSpot Therapeutics is debuting with $45 million from Atlas Venture and Sofinnova Partners to explore allosteric inhibitors against tough-to-drug targets. (16 words)
- [HotSpot Therapeutics to Present Two Poster Presentations on CBL-B Program at AACR Annual Meeting 2023 - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-two-poster-presentations-on-cbl-b-program-at-aacr-annual-meeting-2023.html): BOSTON, Mass.,  Mar. 14, 2023 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (460 words)
- [HotSpot Therapeutics Appoints Eva Jack as Chief Operating Officer - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-appoints-eva-jack-as-chief-operating-officer.html): BOSTON, Mass. (November 17, 2020) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric... (603 words)
- [HotSpot Therapeutics Announces Acquisition of Macroceutics, Inc. - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-announces-acquisition-of-macroceutics-inc.html): BOSTON, Mass. (August 23, 2019)— HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery of nature’s regulatory sites to advance... (580 words)
- [HotSpot Therapeutics Appoints Timothy Reilly as Chief Development Officer - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-appoints-timothy-reilly-as-chief-development-officer.html): BOSTON, Mass. (April 14, 2021) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric... (508 words)
- [Drug hunters explore allostery’s advantages - HotSpot Therapeutics](/content/news_reference/drug-hunters-explore-allosterys-advantages/index.html): After decades of focus on proteins’ active sites, a new crop of biotech firms is shifting attention to proteins’ hidden regulatory pockets (13 words)
- [HotSpot Therapeutics to Present Preclinical Data from CBL-B Program at 2022 Society for Immunotherapy of Cancer Annual Meeting - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-preclinical-data-on-cbl-b-program-at-2022-society-for-immunotherapy-of-cancer-annual-meeting.html): BOSTON, Mass., October 5, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small... (310 words)
- [Privacy Policy - HotSpot Therapeutics](/content/privacy-policy/index.html): Privacy Policy We take data protection very seriously and lay out in our privacy policy what personal information we collect,... (349 words)
- [HotSpot Therapeutics to Present at the Solebury Trout/BMO Fall Private Company Showcase - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-at-the-solebury-trout-bmo-fall-private-company-showcase.html):   BOSTON, Mass. (Oct. 11, 2021) – HotSpot Therapeutics, Inc, a biotechnology company pioneering the discovery and development of first-in-class allosteric... (208 words)
- [HotSpot Therapeutics to Present at the BMO Biopharma Spotlight Series - HotSpot Therapeutics](/content/press_release/hotspot-therapeutics-to-present-at-the-bmo-biopharma-spotlight-series.html): BOSTON, Mass., Feb. 17, 2022 – HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of first- and... (250 words)
- [Float like a butterfly: agility in biotech - HotSpot Therapeutics](/content/news_reference/float-like-a-butterfly-agility-in-biotech/index.html): In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations. (13 words)
- [Moving beyond the active site: why allostery is newly in fashion - HotSpot Therapeutics](/content/news_reference/moving-beyond-the-active-site-why-allostery-is-newly-in-fashion.html): Allosteric pockets on proteins have long been viewed as promising alternatives to active sites for controlling protein function. The problem has been finding them. (13 words)
- [Atlas, Sofinnova Bet $45M on 'HotSpots' - HotSpot Therapeutics](/content/news_reference/atlas-sofinnova-bet-45m-on-hotspots/index.html): Atlas Venture and Sofinnova Partners co-lead investment in a couple of Nimbus alumni (19 words)
- [HotSpot debuts with $45m to find, drug natural allosteric sites - HotSpot Therapeutics](/content/news_reference/hotspot-debuts-with-45m-to-find-drug-natural-allosteric-sites.html): HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. T (20 words)
- [With $45M, HotSpot Takes Drug Research to New Biological Real Estate - HotSpot Therapeutics](/content/news_reference/with-45m-hotspot-takes-drug-research-to-new-biological-real-estate.html): In real estate, location is key. The same holds true in the hunt for new drugs. HotSpot Therapeutics is trying to break new ground in drug discovery by hitting locations on a protein that aren’t the conventional targets of most medicines. (16 words)
- [Hotspot Therapeutics Turns Up The Heat On Natural Allostery - HotSpot Therapeutics](/content/news_reference/hotspot-therapeutics-turns-up-the-heat-on-natural-allostery.html): HotSpot is pioneering a new approach to drugging the allosteric sites that Nature itself uses to control proteins. (17 words)
- [Balancing the Risks and Rewards of Drug Development in China: A Small Biotech CEO Perspective - HotSpot Therapeutics](/content/balancing-the-risks-and-rewards-of-drug-development-in-china-a-small-biotech-ceo-perspective.html): Of the recurring themes that tend to circulate in the drug development discourse,  China is a uniquely fascinating and polarizing... (1,508 words, Mar 17, 2026)
- [A CEO’s Perspective on Navigating Choppy Market Waters - HotSpot Therapeutics](/content/a-ceos-perspective-on-navigating-choppy-market-waters.html): I’m far from the first person to point out the prolonged market challenges that have depressed the biotech fundraising environment... (1,242 words, Nov 13, 2025)
- [A “Complex” Solution to a “Complex” Problem? Attacking KRASG12X Colorectal Cancer Through the CBM Signalosome - HotSpot Therapeutics](/content/a-complex-solution-to-a-complex-problem-attacking-krasg12x-colorectal-cancer-through-the-cbm-signalosome.html): As scientists, we are accustomed to learning something new about targets (and the modulation thereof) that moves the field forward... (918 words, Jul 31, 2025)
- [A New Wave of Therapeutic Innovation Through Targeting Transcription Factors - HotSpot Therapeutics](/content/a-new-wave-of-therapeutic-innovation-through-targeting-transcription-factors.html): In the perpetual and never-ending race by the healthcare sector to unearth new approaches and therapeutics to address disease, one... (967 words, Feb 5, 2025)
- [ESMO Reflections: Glimmers of Hope with the Next Wave of I-O Therapies? - HotSpot Therapeutics](/content/esmo-reflections-glimmers-of-hope-with-the-next-wave-of-i-o-therapies.html): HotSpot’s trip to Barcelona for the recent European Society of Medical Oncology (ESMO) Annual Meeting was no ‘European Vacation,’ but... (821 words, Oct 10, 2024)
- [Has Spring Sprouted New Growth in Immuno-Oncology? - HotSpot Therapeutics](/content/has-spring-sprouted-new-growth-in-immuno-oncology/index.html): As Boston’s weather has started its turn from the frigid darkness that is a northeast winter to the longer days... (1,089 words, May 9, 2024)
- [Drug Discovery: Taking Inspiration from Facial Recognition - HotSpot Therapeutics](/content/drug-discovery-taking-inspiration-from-facial-recognition.html): At HotSpot, we’re harnessing insights from nature by pinpointing specialized protein on/off switches, or pockets, called “natural hotspots.” To date,... (911 words, Feb 7, 2024)
- [Signaling Complexes: A Ripe Opportunity for Drug Development - HotSpot Therapeutics](/content/signaling-complexes-a-ripe-opportunity-for-drug-development.html): Signaling pathways are the intricate networks that govern cell behavior, lying at the crux of cell function. They are used... (942 words, Jan 3, 2024)
- [On the Road at ASCO 2023: Key Takeaways, Observations and Reflections - HotSpot Therapeutics](/content/on-the-road-at-asco-2023-key-takeaways-observations-and-reflections.html): The American Cancer Society for Oncology (ASCO) annual meeting is among the highlights of the clinical oncology calendar. The meeting... (1,077 words, Jul 11, 2023)
- [How We Balance the What and How at HotSpot - HotSpot Therapeutics](/content/how-we-balance-the-what-and-how-at-hotspot/index.html): At HotSpot, we are committed to building something we believe is truly distinctive, setting ourselves apart from our peers in... (346 words, Jun 1, 2023)
- [Moving Our Core Values Beyond Table Stakes - HotSpot Therapeutics](/content/moving-our-core-values-beyond-table-stakes/index.html): Every company has a culture, either by design or default. From our inception in 2016, we wanted to create a... (579 words, Apr 28, 2023)
- [Reimagining I-O with Our First Investigational Drug and a New Approach to Clinical Discovery - HotSpot Therapeutics](/content/reimagining-i-o-with-our-first-investigational-drug-and-a-new-approach-to-clinical-discovery.html): HotSpot Therapeutics recently announced FDA clearance of our Investigational New Drug (IND) application for HST-1011, our small molecule allosteric inhibitor... (604 words, Jan 4, 2023)
- [What Took So Long? – How Tech Has Finally Caught Up with Transcription Factors - HotSpot Therapeutics](/content/what-took-so-long-how-tech-has-finally-caught-up-with-transcription-factors.html): HotSpot Therapeutics recently announced a strategic collaboration with AbbVie to develop IRF5 transcription factor inhibitors for autoimmune diseases. The following blog post provides some valuable real-world perspective on why this initiative is such an important breakthrough in immunology therapeutics. (953 words, Dec 6, 2022)
- [A Turning Point for Immuno-Oncology - HotSpot Therapeutics](/content/a-turning-point-for-immuno-oncology/index.html): Immunotherapy has been the holy grail in the fight against cancer for the last decade. For good reason, we’ve been... (675 words, Nov 10, 2022)
- [Hacking the Human Cell – How Once ‘Un-druggable’ Proteins Became the New Frontier in Drug Development - HotSpot Therapeutics](/content/hacking-the-human-cell/index.html): White Hat Hackers, sometimes called “ethical hackers,” are individuals that work to find and fix security problems in a system... (825 words, Jun 21, 2022)
- [A Global Community - HotSpot Therapeutics](/content/a-global-community/index.html): It is in moments like this that we are reminded of the collective power of good to overcome the disenfranchised and of the incredible impact of even the smallest gestures to shape the course of history. (361 words, Apr 28, 2022)
- [Staying Human in the Age of Artificial Intelligence - HotSpot Therapeutics](/content/staying-human-in-the-age-of-artificial-intelligence.html): No, your next doctor will not be a robot. Nor will an algorithm cure cancer. However, AI technology will absolutely... (1,490 words, Mar 8, 2022)
- [Making R&D ‘Smarter’ by Putting Artificial Intelligence into Practice - HotSpot Therapeutics](/content/making-rd-smarter-by-putting-artificial-intelligence-into-practice.html): The pharmaceutical industry still faces unrelenting challenges across the entirety of the drug development landscape. According to Piper Sandler’s recent... (999 words, Jan 10, 2022)
- [Hitting the Spot - HotSpot Therapeutics](/content/hitting-the-spot/index.html): Today marks an important point in our journey to patients as HotSpot Therapeutics announces its $100MM Series C financing.  This infusion of capital will enable HotSpot to transition into a clinical stage company while supporting further pipeline and platform growth.  (1,253 words, Nov 29, 2021)
- [Immuno-Oncology: The Comeback Kid - HotSpot Therapeutics](/content/immuno-oncology-the-comeback-kid/index.html): Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011 and the seminal initial efficacy disclosure on nivolumab (anti-PD1) in 2012 (Topalian et al NEJM), we can reflect on how I-O has literally changed the lives of tens of thousands of cancer patients and their families. (1,017 words, Jul 13, 2021)
- [Reimagining the Workplace Post Pandemic - HotSpot Therapeutics](/content/reimagining-the-workplace-post-pandemic/index.html): Returning to work following the pandemic presents an opportunity to think creatively about how to re-configure the workplace (1,400 words, Apr 15, 2021)
- [The Business of Science - HotSpot Therapeutics](/content/the-business-of-science/index.html): Today marks an important milestone for HotSpot Therapeutics as we announce our Series B financing, but it also marks a... (1,852 words, May 20, 2020)
- [Hotspots meet DNA-encoded libraries - HotSpot Therapeutics](/content/hotspots-meet-dna-encoded-libraries/index.html): DNA encoded libraries (DEL) have received a lot of attention over the past few years. They’ve been hailed as “highly... (1,066 words, Aug 23, 2019)
- [Targeting the mTORC1 Pathway With Phenotypic Screening - HotSpot Therapeutics](/content/targeting-the-mtorc1-pathway-with-phenotypic-screening.html): The conventional approach to drug discovery shines a light on specific target proteins, using an arsenal of biochemical and virtual... (1,678 words, Jul 31, 2019)
- [Biocentury Innovations shines a new light on allostery - HotSpot Therapeutics](/content/biocentury-innovations-shines-a-new-light-on-allostery.html): I was excited to participate in Allison Johnson’s recent Biocentury article reflecting on the growing interest of industry in allostery and why... (622 words, Jun 30, 2019)
- [Drugging the Undruggable with Allosteric Small Molecules - HotSpot Therapeutics](/content/drugging-the-undruggable-with-allosteric-small-molecules.html): Advances in computational, biophysical and library technologies have driven the emergence of a new drug discovery paradigm with the power... (1,081 words, May 1, 2019)
- [Cats and the future of machine learning in drug discovery - HotSpot Therapeutics](/content/cats-and-the-future-of-machine-learning-in-drug-discovery.html): The predictions around the impact of artificial intelligence (AI) have been broad reaching but it’s clear that not everyone is... (2,897 words, Apr 9, 2019)
- [HotSpot Frequently Asked Questions - HotSpot Therapeutics](/content/hotspot-frequency-asked-questions/index.html): What is a regulatory hotspot? A regulatory hotspot is a privileged allosteric site used by nature to regulate the function... (989 words, Mar 11, 2019)
- [Introducing allokraft - HotSpot Therapeutics](/content/introducing-allokraft/index.html): This is an exciting time for small molecule drug discovery and soon for patients, who have been underserved by current... (454 words, Mar 4, 2019)
- [Following Nature's lead - HotSpot Therapeutics](/content/following-natures-lead/index.html): Lately it seems that allostery is constantly in the news, especially in stories covering a series of high-profile financings by... (1,412 words, Jan 4, 2019)
- [Hotspot Therapeutics Turns Up The Heat On Natural Allostery - HotSpot Therapeutics](/content/hotspot-therapeutics-turns-up-the-heat-on-natural-allostery.html): Most conventional small molecule drugs engage directly with the engine of a protein’s function, aiming to often turning off an... (1,947 words, Jul 17, 2018)
- [Float Like A Butterfly: Agility In Biotech - HotSpot Therapeutics](/content/float-like-a-butterfly-agility-in-biotech/index.html): In the quest towards building high-performing teams, biopharma can lift a page from the tech playbook around agile organizations.  This... (1,227 words, Jun 13, 2018)
- [Allostery: Realizing the promise - HotSpot Therapeutics](/content/allostery-realizing-the-promise/index.html): It starts off with flu-like symptoms and progresses to a perpetual low-grade fever, excessive sweating and loss of appetite.  A... (1,655 words, Mar 5, 2018)

## Listings & Categories

- [Jonathan Montagu, Author at HotSpot Therapeutics](/content/author/jmontagu/index.html) (357 words)
- [Geraldine Harriman, Author at HotSpot Therapeutics](/content/author/gharriman/index.html) (222 words)
- [Tim Reilly, Author at HotSpot Therapeutics](/content/author/treilly/index.html) (65 words)
- [Bruce Booth, Author at HotSpot Therapeutics](/content/author/bbooth/index.html) (34 words)
- [Geraldine Harriman and Tim Reilly, Author at HotSpot Therapeutics](/content/author/geraldine-harriman-and-tim-reilly/index.html) (37 words)
- [Nicholas Keen, Author at HotSpot Therapeutics](/content/author/nkeen/index.html) (32 words)
- [Immuno-oncology Archives - HotSpot Therapeutics](/content/tag/immuno-oncology/index.html) (59 words)
- [Post Archives - HotSpot Therapeutics](/content/tag/post/index.html) (19 words)
- [workplace Archives - HotSpot Therapeutics](/content/tag/workplace/index.html) (19 words)
- [COVID Archives - HotSpot Therapeutics](/content/tag/covid/index.html) (19 words)
- [Amanda Redig, Author at HotSpot Therapeutics](/content/author/aredig/index.html) (39 words)
- [pandemic Archives - HotSpot Therapeutics](/content/tag/pandemic/index.html) (19 words)
- [Ramy Farid and Jonathan Montagu, Author at HotSpot Therapeutics](/content/author/ramy-farid-and-jonathan-montagu/index.html) (39 words)
- [Natural hotspots Archives - HotSpot Therapeutics](/content/category/natural-hotspots/index.html) (183 words)
- [Drug discovery Archives - HotSpot Therapeutics](/content/category/drug-discovery/index.html) (381 words)
- [Leadership Archives - HotSpot Therapeutics](/content/category/leadership/index.html) (99 words)
- [Culture Archives - HotSpot Therapeutics](/content/category/culture/index.html) (170 words)
- [Immunology Archives - HotSpot Therapeutics](/content/category/immunology/index.html) (77 words)

## About Pages

- [Team - HotSpot Therapeutics](/content/team/index.html): Having successfully developed hotspot regulatory binders at other biotechnology companies, our co-founders recognized the opportunity to advance this modality by... (213 words)
- [Contact - HotSpot Therapeutics](/content/contact/index.html) (53 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives